CHE - Chemed Corporation Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

CHE

CHEMED CORPORATION

NYSE

$504.36

▼ DOWN 0.62% (-3.14)

KEY STATISTICS

Market Cap$6.63 B

52w High$557.00

52w Low$365.21

Dividend Yield0.45%

FrequencyQuarterly

P/E23.34

Volume28.62K

Shares Out.13.07M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Kevin J. McNamara

COMPENSATION 2026

Salary$1,604,000

Stock Awards$2,511,638

Incentive Plan Pay$2,923,712

All Other Comp.$1,312,650

Total$12,625,106

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 3, 1973

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

15,811

PRICE TARGET

Target High$650.00

Target Low$650.00

Target Median$650.00

Target Consensus$650.00

UPCOMING EARNINGS

DateOct 27, 2026

DayTuesday

Rev. Est.$685.04M

OCT

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2005-05-12	Forward	2:1
1981-11-12	Forward	2:1

ETFS HOLDING THIS STOCK

ETFS HOLDING

295

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

100.00%

HOLDERS

825

TOP 8 OF 825 · RANKED BY POSITION SIZE

Metatron Capital Sicav Plc

Blackrock Fund Advisors

1.3M sh

$205.3M

Aqr Capital Management LLC

972.5K sh

$446.21M

Kayne Anderson Rudnick Investment Management LLC

PRICE

$504.36 ▼ DOWN 0.62% (−$3.14)

OVERLAYS

About Chemed Corporation

https://www.chemed.com ↗

Chemed Corporation, founded in 1970 and based in Cincinnati, Ohio, offers hospice and palliative care through VITAS and provides plumbing, drain cleaning, and water restoration services via Roto-Rooter to residential and commercial customers in th...

INDUSTRY

Medical - Care Facilities

A SERVICE CHEMED CORPORATION IS KNOWN FOR

VITAS Hospice and Palliative Care Services

Chemed Corporation, through VITAS Healthcare, primarily offers hospice and palliative care for terminally ill patients, delivering medical, emotional, and spiritual support via a network of healthcare professionals.

COMPETITORS

COMPETITOR

ADUS COMPARE

BTSG COMPARE

PNTG COMPARE

Chemed in 2025

SENTIMENT: − NEGATIVE

EARNINGS · JULY 2025

Chemed Shares Tumble After Missing Q2 2025 Earnings, Slashing Full-Year Guidance, and Announcing Executive Departure

Chemed Corporation's second-quarter 2025 earnings report significantly missed analyst expectations for both earnings per share and revenue. This, coupled with a substantial downward revision of the company's full-year earnings guidance, triggered a significant drop in the company's stock price. The announcement was further compounded by the news of the departure of Nicholas M. Westfall, the Chairman and CEO of Chemed's VITAS Healthcare subsidiary.

LEADERSHIP STRATEGY · JULY 29, 2025 · COMPLETED

Chemed Appoints New CEO for VITAS Healthcare Amidst Performance Challenges and Guidance Cut

Chemed announced the departure of Nicholas M. Westfall, the long-time CEO of its VITAS Healthcare subsidiary, and named Joel L. Wherley as his successor. This significant leadership transition occurred as the company concurrently announced a substantial downward revision of its full-year 2025 earnings guidance, primarily due to profitability challenges within the VITAS segment related to Medicare Cap limitations in Florida.

Latest News

GLOBENEWSWIRE · OCT 1, 2026

Chemed To Report Third Quarter 2026 Earnings October 27, Related Conference Call To Be Held On October 28

CINCINNATI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, October 27, 2026, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m.

READ ARTICLE